Overexpression of CDC25B and LAMC2 mRNA and Protein in Esophageal Squamous Cell Carcinomas and Premalignant Lesions in Subjects from a High-Risk Population in China

• Published in: Cancer epidemiology, biomarkers & prevention Vol. 17; no. 6; pp. 1424 - 1435
• Main Authors: Shou, Jian-Zhong, Hu, Nan, Takikita, Mikiko, Roth, Mark J., Johnson, Laura Lee, Giffen, Carol, Wang, Quan-Hong, Wang, Chaoyu, Wang, Yuan, Su, Hua, Kong, Li-Hui, Emmert-Buck, Michael R., Goldstein, Alisa M., Hewitt, Stephen M., Taylor, Philip R.
• Format: Journal Article
• Language: English
• Published: Philadelphia, PA American Association for Cancer Research 01.06.2008
• Subjects: Biological and medical sciences; Carcinoma, Squamous Cell - genetics; cdc25 Phosphatases - genetics; CDC25B; China - epidemiology; early detection; esophageal cancer; Esophageal Neoplasms - genetics; Esophagus; Female; Gastroenterology. Liver. Pancreas. Abdomen; Gene Expression Profiling; Humans; Immunoenzyme Techniques; LAMC2; Laminin - genetics; Linear Models; Male; Medical sciences; Middle Aged; Precancerous Conditions - genetics; Proportional Hazards Models; Protein Array Analysis; quantitative reverse transcription-PCR; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger - metabolism; survival; tissue microarray; Tumors; Asia; China; China, People's Rep; Human; High risk; Premalignant lesion; Esophageal disease; Esophagus squamous cell carcinoma; Gene overexpression; Malignant tumor; Esophagus cancer; Protein; Cancerology; Messenger RNA; Digestive diseases; Population; Cancer
• ISSN: 1055-9965; 1538-7755
• DOI: 10.1158/1055-9965.EPI-06-0666

Molecular events associated with the initiation and progression of esophageal squamous cell carcinoma (ESCC) remain poorly understood but likely hold the key to effective early detection approaches for this almost invariably fatal cancer. CDC25B and LAMC2 are two promising early detection candidates emerging from new molecular studies of ESCC. To further elucidate the role of these two genes in esophageal carcinogenesis, we did a series of studies to ( a ) confirm RNA overexpression, ( b ) establish the prevalence of protein overexpression, ( c ) relate protein overexpression to survival, and ( d ) explore their potential as early detection biomarkers. Results of these studies indicated that CDC25B mRNA was overexpressed (≥2-fold overexpression in tumor compared with normal) in 64% of the 73 ESCC cases evaluated, whereas LAMC2 mRNA was overexpressed in 89% of cases. CDC25B protein expression was categorized as positive in 59% (144 of 243) of ESCC cases on a tumor tissue microarray, and nonnegative LAMC2 patterns of protein expression were observed in 82% (225 of 275) of cases. Multivariate-adjusted proportional hazard regression models showed no association between CDC25B protein expression score and risk of death [hazard ratio (HR) for each unit increase in expression score, 1.00; P = 0.90]; however, several of the LAMC2 protein expression patterns strongly predicted survival. Using the cytoplasmic pattern as the reference (the pattern with the lowest mortality), cases with a diffuse pattern had a 254% increased risk of death (HR, 3.52; P = 0.007), cases with no LAMC2 expression had a 169% increased risk of death (HR, 2.69; P = 0.009), and cases with a peripheral pattern had a 130% greater risk of death (HR, 2.30; P = 0.02). CDC25B protein expression scores in subjects with esophageal biopsies diagnosed as normal ( n = 35), dysplastic ( n = 23), or ESCC ( n = 32) increased significantly with morphologic progression. For LAMC2, all normal and dysplastic patients had a continuous pattern of protein expression, whereas all ESCCs showed alternative, noncontinuous patterns. This series of studies showed that both CDC25B and LAMC2 overexpress RNA and protein in a significant majority of ESCC cases. The strong relation of LAMC2 pattern of protein expression to survival suggests a role in prognosis, whereas the association of CDC25B with morphologic progression indicates a potential role as an early detection marker. (Cancer Epidemiol Biomarkers Prev 2008;17(6):1424–35)